Fulcrum Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Fulcrum Therapeutics's estimated annual revenue is currently $22M per year.
- Fulcrum Therapeutics received $80.0M in venture funding in September 2018.
- Fulcrum Therapeutics's estimated revenue per employee is $217,921
- Fulcrum Therapeutics's total funding is $478.3M.
Employee Data
- Fulcrum Therapeutics has 101 Employees.
- Fulcrum Therapeutics grew their employee count by 1% last year.
Fulcrum Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | Chief Financial Officer | Reveal Email/Phone |
2 | Chief Medical Officer | Reveal Email/Phone |
3 | Chief People Officer | Reveal Email/Phone |
4 | VP | Reveal Email/Phone |
5 | VP Quality Assurance | Reveal Email/Phone |
6 | SVP, Regulatory Affairs & Quality Assurance | Reveal Email/Phone |
7 | VP Drug Safety & Pharmacovigilance | Reveal Email/Phone |
8 | VP, Head Strategy & Program Lead | Reveal Email/Phone |
9 | SVP, Business and Corporate Development | Reveal Email/Phone |
10 | VP, Program Strategy Leader FTX-6058 a.i. | Reveal Email/Phone |
Fulcrum Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Fulcrum Therapeutics?
What if we could regulate genes, not just discover them What if we could treat disease at their genetic source What if we could integrate multiple disciplines to develop breakthrough medicines What if you could be a part of a passionate team committed to the patients we serve We can. We will. We Are. Join Us. We are here to develop new medicines to deliver a new future for patients and their families by transforming gene regulation in disease. A fulcrum is defined as the point on which a lever rests, balances and pivots. Fulcrum Therapeutics is intervening in gene regulatory mechanisms to unlock the information contained in the human genome. The Fulcrum product engine is dedicated to bringing balance to the genetic on and off switches in disease. Our Approach The sequencing of the human genome has provided incredible insight into disease biology, yet the richness of biology comes from the dynamic on and off switches that control the genome gene regulation. The Fulcrum product engine is based on the breakthrough biology of gene regulation. It will bring to bear medicines for devastating diseases across multiple therapeutic areas by modulating or balancing the expression of the genes known to drive disease. By focusing on disease causative genes, we are taking a highly personalized approach to treating disease unlocking the druggable mechanisms that regulate disease genes to develop a new generation of disease-modifying therapies.
keywords:N/A$478.3M
Total Funding
101
Number of Employees
$22M
Revenue (est)
1%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Fulcrum Therapeutics News
Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with...
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare...
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare...
CAMBRIDGE, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it has priced an underwritten public offering of 6,600 ...
Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced multiple presentations at the 28th Annual FSHD Society International Research Congress (IRC). June 24, 2021 IR ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $15.7M | 101 | -16% | $380.7M |
#2 | $15.7M | 101 | 63% | $203M |
#3 | $14.6M | 101 | 6% | $28.8M |
#4 | $15.7M | 101 | -6% | N/A |
#5 | $23.9M | 102 | -3% | N/A |
Fulcrum Therapeutics Funding
Date | Amount | Round | Lead Investors | Reference |
---|---|---|---|---|
2016-07-20 | $55.0M | A | Third Rock Ventures | Article |
2017-05-11 | $Undisclosed | A | Google Ventures | Article |
2018-09-06 | $80.0M | B | Foresite Capital | Article |